2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole(CAS#172152-36-2)

2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole(CAS#172152-36-2)

pharmachologic effect
Ilaprazole is a proton pump inhibitor that specifically acts on the parietal cells of the gastric mucosa. It enters the secretory tubule of parietal cells, converts into the active form of sulfinamide in this high-acid environment, and irreversibly combines with the sulfhydryl group of the proton pump through disulfide bonds to generate a complex of sulfinamide and proton pump, thereby inhibiting the activity of the proton pump, blocking the last step of gastric acid secretion, and producing the effect of inhibiting gastric acid secretion.
Clinical application
It is mainly used for the treatment of acid-related diseases such as duodenal ulcer and reflux esophagitis. For patients with excessive gastric acid secretion, resulting in damage to the gastric mucosa and duodenal mucosa, ilaprazole can inhibit gastric acid secretion, increase the pH value in the stomach and duodenum, and create a good environment for the repair of the damaged mucosa, thereby alleviating symptoms such as heartburn, acid reflux, and epigastric pain.
security
During use, some adverse reactions may occur, such as diarrhea, dizziness, headache, abnormal liver function, etc., but the general symptoms are relatively mild and can be tolerated by most patients. However, caution is required in patients with severe hepatic impairment, as the metabolism of the drug in the body may be affected, increasing the risk of adverse effects.
Synthesis method
Generally, 2-chloromethyl-4-methoxy-3-methylpyridine is used as the starting material, and the corresponding thioether is formed by reaction with mercaptan, and then sulfoxide is obtained by oxidation reaction, and then a series of steps such as condensation reaction with 5-pyrrole-1H-benzimidazole are carried out to finally synthesize ilaprazole.